

## DAFTAR PUSTAKA

- Abid, A., Subhani, F., Kayani, F., Awan, S., Abid, S. 2020. Drug-induced liver injury is associated with high mortality-A study from a tertiary care hospital in Pakistan. PLoS ONE 15(4).
- Amarapurkar, D.N. 2011. Prescribing Medications in Patients with Decompensated Liver Cirrhosis. *Internasional Journal of Hepatology*, vol 2011:519526.
- Anindyaguna, A., Mustofa, S., Anggraini, D.I., Oktarlina, R.Z. 2022. Drug-Induced Liver Injury Akibat Penyalahgunaan Parasetamol. *Medula*. Vol 12:3.
- Bacon, B.R. 2010. Cirrhosis and its Complication. In: Longo, D.L., & Fauci, A.S. *Harrison's Gastroenterology and Hepatology*. USA: The McGraw-Hill Companies Inc. Pp. 419-433.
- Badan POM RI 2015. Pusat Informasi Obat Nasional. <https://pionas.pom.go.id/ioni/lampiran-2-gagal-hati-0>. [diakses 21 November 2022].
- Bai, Z., Cheng, G., Sanchez, N.M., Qi, X., 2021. Human albumin infusion strategy in liver cirrhosis: liberal or restrictive?. *Annals of Translational Medicine*. Volume 9(14).
- Barman, M., Al-Hariri, B., Mustafa, A.R., Ambra, N., Amjed, I., Alharafsheh, A.E.N., Illahi, M.N., Hamuda, S., Gaafar, M., Sharif, M. 2022. Ceftriaxone-induced hepatotoxicity in patients with common medical infections in Qatar: A retrospective study. *Qatar Med J*. Volume 3(27).
- Bazinet, R.P., Layé, S. 2014. Polyunsaturated Fatty Acids And Their Metabolites In Brain Function And Disease. *Nature Rev Neurosci*. 15(12):771.
- Bernardi, M., Maggioli, C., Zaccherini, G. 2012. Human albumin in the management of complications of liver cirrhosis. *Crit Care*. Dec 12;16(2):211.
- Björnsson, E.S. 2016. Hepatotoxicity by Drugs: The Most Common Implicated Agents. *Int J Mol Sci*. 17(2):224.
- Björnsson, E.S dan Hoofnagle, J.H. 2015. Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports. *Hepatology*. Volume 63 hal.590-603.
- Boland, B.S., Dong, M.H., Bettencourt, R., Barret-Connor, E., Loomba, R. 2014.

- Association of serum bilirubin with aging and mortality. *J.Clin.Exp.Hepatol*, 4(1):1-7.
- Budingen, F.V. 2014. Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments. *Ther Adv Infect Dis*. 2(1):17-42.
- Cano, A.P., Cifuentes, L.P., Amariles, P. 2017. Structured Literature Review of Hepatic Toxicity Caused by Medicines. *Rev Colomb Gastroenterol*. Volume 32 (4).
- Cheema, E., Al-Aryan, A., Al-Hamid, A. 2019. Medicine use and medicine-related problems in patients with liver cirrhosis: a systematic review of quantitative and qualitative studies. *Eur J Clin Pharmacol*. 75:1047-1058.
- Cheney, C.P., Goldber, E.M., Chopra, S. 2012. Cirrhosis and Portal Hypertension: an overview. In: Friedman, L.S, Kheffe, E.B. *Handbook of Liver Disease*. Philadelphia: Elsevier Inc. Pp. 136-148.
- Clarasanti, I., Marthen, C.P.W., Bradley, J.W. 2016. Gambaran Enzim Transaminase pada Pasien Tuberkulosis Paru yang Diterapi dengan Obat obat Anti Tuberkulosis di RSUP Prof. Dr. R. D. Kandou. *Jurnal e-Clinic* Vol. 4, No. 1.
- Chintya, S.E., Pradipta, I.S., Abdulah, R. 2012. Penggunaan obat penginduksi kerusakan hati padapasien rawat inap penyakit hati. *Jurnal Farmasi Klinik Indonesia*, volume 1:2.
- Danastri, C.N. 2013. Sirosis hepatitis pada pasien dengan riwayat mengkonsumsi alkohol kronik. *Medula*, Volume 1, Nomor 2.
- Dancygier, H. 2010. *Clinical Hepatology Principles and Practice of Hepatobiliary Diseases*. USA: Springer International Publishing. Pp. 949- 965.
- Daulay, A.Z., Harahap, A., Hiswani. 2012. Karakteristik penderita sirosis hati yang dirawat inap di RS Haji Medan. [Thesis]. Medan. Fakultas Kedokteran. Universitas Sumatera Utara.
- Dewi, T., Masruhim, M.A., Sulistiarini, M. 2016. Identifikasi Obat Penginduksi Kerusakan Hati Pada Pasien Hepatitis Di Rumah Sakit Abdul Wahab Sjahranie. *Dalam Seminar Nasional Kefarmasian Ke-III*. Samarinda, 20-21 April 2016. Samarinda. Fakultas Farmasi Universitas Mulawarman.hal 151-157.

- Dipiro, J.T., Dipiro, C.V., Wells, B.G., & Scwinghammer, T.L. 2017. *Pharmacotherapy Handbook Tenth Edition*. USA : McGraw-Hill Company.
- Dotulong, J. F. J., Sapulete, M. R. dan Kandou, G. D. 2015. Hubungan Faktor Risiko Umur, Jenis Kelamin Dan Kepadatan Hunian Dengan Kejadian Penyakit Tb Paru Di Desa Wori Kecamatan Wori. *Jurnal Kedokteran Komunitas Dan Tropik*, 3(2), pp. 57–65.
- Elzouki, Safitri, A.R., Mutia. 2020. Evaluasi Obat-Obatan Berpotensi Hepatotoksik Pada Pasien Dengan Gangguan Fungsi Hepar Di Ruang Rawat Inap Ulin Banjarmasin. *Jurnal Pharmascience*. Vol. 1(2): 16-26.
- Emily, S., dan Paul, D. 2013. Prescribing in Patients with Abnormal Liver Function Tests. *Aust Fam Physician*. 42(1-2):30-3.
- Engin, M.M.N. 2019. Approach to Disorders in Liver Function Tests in Children. *Jurnal Medical* vol. 1(1): 105.
- European Association for the Study of the Liver. 2018. Clinical Practice Guidelines on the Management of Ascites, Spontaneous Bacterial Peritonitis, And Hepatorenal Syndrome In Cirrhosis. *Journal of Hepatology*. 53:397–417.
- Fajrian, F.M. 2020. Enzim Transferase dengan Bilirubin Total Penderita Ikterus Obstruktif. *Jurnal Ilmiah Kesehatan Sandi Husada*, VOL. 11(1):176-182.
- Fariz, K.K., Rinaldi, C., Lesmana, A., Sulaiman, A.S., Gani, R.A., Hasan, I. 2019. Profil Klinis Pasien Sirosis Hati dengan Varises Esofagus yang Menjalani Ligasi Varises Esofagus di Rumah Sakit Dr. Cipto Mangunkusumo. *J.Penyakit Dalam Indonesia*.
- Foster, G.R., Irving, W.L., Cheung, M.C. 2016. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. *J Hepatol*. 64:1224-31.
- Fukui, H., Kawaratani, H., Kaji, K., Takaya, H., Yoshiji, H. 2018. Management of Refractory Cirrhotic Ascites: Challenges and Solutions. *Hepat Med*. 10:55-71.
- Gentile, J.A., Boone, L.B., Kyle, J.A., Kyle, L.R. 2020. Drug Considerations for Medication Therapy in Cirrhosis. *US Pharm Gastroenterology*. 45(12):9-12.
- Goldberg, E., Chopra, S. 2015. Cirrhosis In Adults: Etiologies, Clinical Manifestations and Diagnosis. *Gazy University*, 1-25.
- Hall, P., Johnny, C. 2012. What is the real function of the liver ‘function’ test?.

- Ulster Med J. 81:30-36.
- Haurissa, A.E. 2014. Gamma Glutamyl Transferase Sebagai Biomarker Risiko Penyakit kardiovaskular. CDK-222 vol. 41(11) : 816- 18.
- Hikmah E.N dan Mutmainah N. 2014. Penggunaan Obat-Obatan Penginduksi Penyakit Liver Terhadap Pasien Gangguan Fungsi Liver Di Rumah Sakit X Surakarta Tahun 2013. [Skripsi]. Surakarta. Fakultas Farmasi. Universitas Muhammadiyah Surakarta.
- Hustead, T.R., Oh, R.C., Ali, S.M., Pantsari, M.W. 2017. Mildly Elevated Liver Transaminase Levels: Causes and Evaluation. Am Fam Physician. 96(11):709-715.
- Imelda, R. 2012. Profil pasien sirosis hati di ruang rawat inap penyakit dalam RSUP H. Adam Malik Medan. Medan:Universitas Sumatera Utara.
- Jagdish, R.K. 2012. Profil pasien sirosis hati di ruang rawat inap penyakit dalam RSUP H. Adam Malik Medan. Medan: Universitas Sumatera Utara.
- Jevas, C. 2017. Physiology of the Liver. International Journal of Research in Pharmacy and Biosciences vol.4:8 hal.13-24.
- Joshi, D., Keane, G., Brind, A. 2015. Hepatology at a Glance, First Edition. John Wiley & Sons, Ltd.
- Katarey., Dev, V., Sumita. 2016. Drug-induced Liver Injury. Clinical Medicine s104–s109.
- Kaufmann, C., Stamfli, D., Heresberger, K.E., Lampert, M.L. 2015. Determination of risk factors for drug-related problems: A multidisciplinary triangulation process. BMJ Open, 5(3), pp. 1–7.
- Kementerian Kesehatan RI. 2018. Hasil Riset Kesehatan Dasar (Riskesdas) 2018. Jakarta: Badan Penelitian dan Pengembangan Kesehatan.
- Khalili, M., & Burman, B. 2014. Liver Disease Pathophysiology of Disease: An Introduction To Clinical Medicine, Ed. 7th. USA: The McGraw-Hill Companies.
- Kuncoro, H., Primadharsini, P.P., Mariasi, I.K., Somayana, G., Suryadarma, I.G.A., Purwadi, N., Wibawa, I.D.N. 2017. Kadar Resistin Serum Berhubungan dengan Skor child-turcotte pugh Pada Penderita Sirosis Hati. Jurnal Penyakit Dalam Udayana. Volume 1, No.1, hal.30-37.

- Lala, V., Zubair, M., Minter, D.A. 2023. Liver function tests. StatPearls Publishing.
- Lamtota, I. 2013. Profil pasien sirosis hati yang dirawat inap di RSUP Haji Adam Malik Medan. [Thesis]. Medan. Fakultas Kedokteran. Universitas Sumatera Utara.
- Larsen, M.T., Kuhlmann, M., Hvam, M.L., Howard, K.A. 2016. Albumin-based drug delivery: Harnessing nature to cure disease. *Moll. Cell. Ther.* 4:3.
- Lee, J.C., Kim, J.S., Kim, H.W., Cho, I.K., Lee, J., Jang, E.S., Lee, S.H., Hwang, J.H., Kim, J.W., Jeong, S.H., Kim, J. 2018. Outcome of Endoscopic Retrograde Cholangiopancreatography in Patients With Clinically Defined Decompensated Liver Cirrhosis. *J Dig Dis.* 19(10):605-613.
- Leonor, P.P., Iciar, M.L., Pere, V.B., Francisc, P.L., Olga, D.S. 2012. Drug Dosage Recommendations in Patients With Chronic Liver Disease. *Rev.esp.enferm.dig.* vol. 104(4).
- Liana, J., Robiyanto., Purwanti, N.U. 2018. Penggunaan hepatoprotektor pada pasien sirosis hati rawat inap di rsud dokter soedarso kalimantan barat tahun 2017. *Jurnal Pharmascience.*
- LiverTox. 2021. Kortikosteroid. In: *LiverTox: Clinical and Research Information on Drug-Induced Liver Injury* [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases.
- LiverTox. 2018. Insulin. In: *LiverTox: Clinical and Research Information on Drug-Induced Liver Injury* [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases.
- LiverTox. 2018. Kaptopril. In: *LiverTox: Clinical and Research Information on Drug-Induced Liver Injury* [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases.
- LiverTox. 2019. Omeprazole. In: *LiverTox: Clinical and Research Information on Drug-Induced Liver Injury* [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases.
- LiverTox. 2019. Categorization Of The Likelihood Of Drug Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases.
- LiverTox. 2020. Metformin. In: *LiverTox: Clinical and Research Information on*

- Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases.
- Loomba, R., Friedman, S.L. & Shulman, G.I. 2021. Mechanisms and disease consequences of nonalcoholic fatty liver disease. *Cell*. 184:2537–2564.
- Lorensia, A., Wijaya, R. 2016. Hubungan Jumlah Obat yang Digunakan terhadap Risiko Terjadinya Drug-Related Problems pada Pasien Asma di Suatu Rumah Sakit di Surabaya. *J. Trop. Pharm. Chem*, Volume 3, No. 3.
- Lovena, A., Miro, S., Efrida, E. 2017. Karakteristik Pasien Sirosis Hepatis Di RSUP Dr. M. Djamil Padang. *J Kesehatan Andalas*.
- Lu, R.J., Zhang, Y., Tang, F.L. 2016. Clinical characteristic of drug-induced liver injury and related risk factors. *Experimental and Therapeutic Medicine*, volume 12: 2606-2616.
- Luklukaningsih, Zuyina. 2014. *Anatomi Fisiologi dan Fisioterapi*. Yogyakarta: Nuha Medika.
- Malau, D.L. 2013. Karakteristik penderita sirosis hati yang dirawat di RSUD Sidikalang. Medan: Universitas Sumatera Utara.
- Marselina, N.M. 2014. *Gambaran Klinis Pasien Sirosis Hati: Studi Kasus di RSUP DR Kariardi Semarang Periode 2010-2012*. Semarang: Universitas Diponegoro.
- Moman, R.N., Gupta, N., Varacallo, M. 2022. *Fisiologi, Albumin*. Penerbitan StatPearls.
- Moon, A.M., Singal, A.G, Tapper, E.B. 2020. Contemporary epidemiology of chronic liver disease and cirrhosis. *Clin. Gastroenterol. Hepatol*. 18:2650–2666.
- Muacevic, A dan Adler, J.R. 2021. Hepatotoxicity secondary to levofloxacin use. *Cureus*. 13(6):e15973.
- Nessa ML, Yusuf F, Mudatsir. 2017. Hubungan Child Pugh Score dengan Kualitas Hidup pada Pasien Sirosis Hati di Bagian Penyakit Dalam RSUDZA Banda Aceh. *Jurnal Ilmiah Mahasiswa Kedokteran Biomedis*. 2(4): 24-34.
- Newsome, P.N., Cramb, R., Davison, S.M. 2017. Guidelines on The Management of Abnormal Liver Blood Tests. *Gut*. 67:6–19.
- Nigatu, A., Yap, J.E., Lee, C.K., Go, B., Doukky, R. 2019. Bleeding Risk of Transesophageal Echocardiography in Patients With Esophageal Varices. *J Am Soc Echocardiogr*. 32(5):674-676.e2.

- Noor, C., Safitri, S., Mutia, A.R. 2014. Evaluasi Obat-obatan Berpotensi Hepatotoksik pada Pasien Dengan Gangguan Fungsi Hepar di Ruang Rawat Inap RSUD Ulin Banjarmasin. *Jurnal Pharmascience* vol.1(2).
- Nurdjanah, S. 2014. Sirosis Hati. Dalam Buku Ajar Ilmu Penyakit Dalam, edisi 6, jilid 2, hal 1978-1983. Jakarta: Internal publishing.
- Oettl, K., Birner, G.R., Spidelboeck, W., Stueger, H.P., Dorn, L., Stadlbauer, V., Putz-Bankuti, C., Krisper, P., Graziadei, L., Vogel, W. 2013. Oxidative albumin damage in chronic liver failure: Relation to albumin binding capacity, liver dysfunction and survival. *J. Hepatol.* volume 59:978-983.
- Oktaviani, I. 2012. Aspek Farmakokinetika Klinik Obat-Obat yang Digunakan pada Pasien Sirosis Hati di Bangsal Interne RSUP Dr. M. Djamil Padang. Padang: Laporan Kasus.
- Pandit, A., Sachdeva, T., Bafna, P. 2012. Drug-Induced Hepatotoxicity: A Review. *Journal of Applied Pharmaceutical Science* 02 (05): 233-243.
- Parsian, H., Nouri, M., Rahimipour, A., Hossein, M., & Qujeq, D. 2011. Comparison of Five Liver Fibrosis Indexes with Serum Levels of Laminin and N Terminal Peptide of Procollagen Type III in Chronic Hepatitis Patients. *Liver Biopsy*.
- Patasik, Y.Z., Waleleng, B.J., Wantania, F. 2015. Profil Pasien Sirosis Hati Yang Dirawat Inap Di Rsup Prof. Dr. R. D. Kandou Manado Periode Agustus 2012 Agustus 2014. *Jurnal e-Clinic (eCl)*. 3(1):342-347.
- Pleguezuelo, M., Benitez, J.M., Jurado, J., Montero, J.L., Mata, M.D. 2013. Diagnosis and Management of Bacterial Infections in Decompensated Cirrhosis. *World J Hepatol.* 5(1):16-25.
- Privitera, G., Figorilli, F., Jalan, R., Mehta, G. 2018. Portosystemic Shunt Embolization and Recurrent Ascites: A Single-Center Case Series. *Gastroenterology* 155(5):1649-1650.
- Rahmayati, E., Al-Asbana, Z., Aprina. 2017. Faktor-faktor yang berhubungan dengan lama perawatan pasien pasca operasi di ruang rawat inap bedah rumah sakit. *Jurnal Keperawatan*, Volume 13, No. 2.
- Ramachandran, A., Jaeschke, H. 2017. Mechanisms of acetaminophen and their translation to the human pathophysiology. *J Clin Transl Res.* 3(1): 157–169.
- Rasyid, S.A., Armayani, A., Yuniati, Y., Lio, T.M.P. 2020. Analysis of serum

- glutamic pyruvic transaminase and serum glutamic oxaloacetic transaminase levels in tuberculosis patients in Kendari City General Hospital, Indonesia. *Infect Dis Rep*. Volume 12:8737.
- Robert, S. Rahimi, Don, C. Rockey. 2012. Complications of Cirrhosis. *Curr Opin Gastroenterol* 28(3):223-229.
- Robiyanto, R., Liana, J., Purwanti, N.U. 2019. Kejadian Obat-obatan Penginduksi Kerusakan Liver pada Pasien Sirosis Rawat Inap di RSUD Dokter Soedarso Kalimantan Barat. *Jurnal Sains Farmasi & Klinis* 6(3):274-285.
- Rostom, H., Shine, B. 2018. Basic Metabolism: proteins. *Surg*. 36:4:153-8.
- Rutledge, S.M., Asgharpour, A. 2020. Smoking and liver disease. *Gastroenterol Hepatol*, 16(12):617-625.
- Samarang, S., Syukur, S.B., Syamsuddin, F. 2023. Hubungan average length of stay (AVLOS) dengan tingkat kecemasan keluarga pasien di ruangan ICU RSUD Otanaha. *Jurnal Ilmu Kesehatan dan Gizi*. Volume 1 nomor 2.
- Sanchez, W., Talwalkar, J.A. 2012. *Liver Cirrhosis*. Mayo College of Medicine: San Antonio.
- Samonakis, D.N., Koulentaki, M., Coucotsi, C., Augoustaki, A., Baritaki, C., Digenakis, E., Papiamonis, N., Fragaki, M., Matrella, E., Tzardi, M., Kouroumalis, E.A. 2014. Clinical Outcomes of Compensated and Decompensated Cirrhosis: A long term study. *World Journal of Hepatology* 6(7):504-512.
- Setiawan, M. 2011. Hubungan Antara Kejadian Asites Pada Cirrhosis Hepatis Dengan Komplikasi *Spontaneous Bacterial Peritonitis*. *Journal UMM*. 7(15).
- Sharma, B., & John, S. 2022. *Hepatic Cirrhosis*. StatPearls Publishing.
- Shi, J., Zhang, Y., Gu, W., Cui, B., Xu, M., Yan, Q., Wang, W., Ning, G., Hong, K. 2012. Serum Liver Fatty Acid Binding Protein Levels Correlate Positively With Obesity and Insulin Resistance in Chinese Young Adults. *PLoS One* 7;7(11).
- Sibuea, C.V., Hutabarat, E.S.K., & Simangunsong, D.M. 2022. Viabilitas Hepatosit pada Monokultur 3D Metode Hanging Drop dan Monokultur 2D. *Nommensen Journal of Medicine* 7(2):36-38.
- Silaban, B.P., Lumongga, F., Silitonga, H. 2020. Karakteristik Penderita Sirosis Hati: Literatur Review. *Jurnal Kedokteran Methodist*, vol.13:2.



- Soeters, P.B., Wolfe., R.R., Shenkin, A. 2019. Hypoalbuminemia: Pathogenesis and clinical significance. *J. Parenter. Enter. Nutr.* 43:181-193.
- Sofwanhadi. 2012. Anatomi Hati. *Dalam* Sulaiman, A.H., Akbar, H.N., Lesmana, L.A., & Noer, H.M.S., editor. *Buku Ajar Ilmu Penyakit Hati*. Jakarta: Sagung Seto. hal. 1-3.
- Sonderup, M.W. 2011. Drug Induced Liver Injury: Drug-Induced Liver Injury Is A Significant Cause Of Liver Disease. Including Chronic Liver Disease. *Continuing Medical Education* 29(6): 2442–2446.
- Steven, L.R., Orlee, R.G., Anna, F.L., Christine, V., Nicole, M.H., Richard, A.S., K.C. 2020. Spectrum of Disease in Children and Adolescents. *Journal of the American Heart Association*.
- Sudoyo, A.W., Setiyohadi, B., Alwi, I., Setiati, S. 2010. *Buku Ajar Ilmu Penyakit Dalam*, Jilid II. Ed. V. Jakarta: Balai Penerbit FK UI.
- Syifa, M. 2015. Ensefalopati Hepatik pada Sirosis Hati: Faktor Presipitasi dan Luaran Perawatan di RSUD dr. Saiful Anwar Malang. *Jurnal Kedokteran Brawijaya* 28(4):340-344.
- Tajiri K dan Shimizu Y. 2008. Practical Guidelines for Diagnosis and Early Management of Drug-Induced Liver Injury. *World J Gastroenterol* Vol 14 No.44:6774–6785.
- Tambunan, A, Mulyadi, Y, Kahtan M.I. 2013. Karakteristik Pasien Sirosis Hati di RSUP Dr. Soedarso Pontianak periode Januari 2008 - Desember 2010. *Jurnal Mahasiswa PSPD FK Universitas Tanjungpura* 2(1):1-19.
- Tasnif, Y dan Hebert, M. 2013. *Complications of End-Stage Liver Disease*, dalam: *Applied Therapeutic The Clinical Use of Drugs*. Wolter Kluwers, Lippincott.
- Teschke, R., Danan, G. 2017. Drug-induced liver injury: Is chronic liver disease a risk factor and a clinical issue?. *Expert Opin Drug Metab Toxicol* 13(4):425–438.
- Tsao, G.G. 2012. Cirrhosis and its sequel. Dalam: Goldman L, editor (penyunting). *Goldman's Cecil Medicine*. Edisi ke-24 hlm.999-1007. Philadelphia: Elsevier.
- Tsochatzhis, E.A., Bosch, J., Burroughs, A.K. 2014. Liver Cirrhosis. *The Lancet*. Vol. 383(9930):1749-61.
- Virgonita, S., Zulkarnaen, A.K. 2012. Pola Penggunaan Obat pada Pasien Sirosis

- Hati di Instalasi Rawat Inap Bangsal Penyakit Dalam Rumah Sakit Dr. Sardjito Yogyakarta. *Majalah Farmsetik*, Vol. 8 No. 3.
- Walayat, S., Martin, D., Patel, J., Ahmed, U., Asghar, M.N., Pai, A.U., Dhillon, S. 2017. The role of albumin in cirrhosis: from a hospital perspective. *J.Community Intern Med Perspect*. Volume 7(1):8-14.
- WHO. 2013. Global Health Estimates Summary Tables: Projection of deaths, by cause, age and sex. [http://www.who.int/healthinfo/global\\_burden\\_disease/en/](http://www.who.int/healthinfo/global_burden_disease/en/).
- Wojtowicz, Ewa Jagiello; Elzbieta Baran, Grazyna Krawczuk dan Violetta Szklarczyk. 2007. Testosterone, Estradiol, Progesterone and Sex Hormone Binding Globulin (SHBG) Blood Serum Levels in Men with Acute Viral Hepatitis A or B. *Med Sci Monit* Volume 3 Nomor 5 : 686-691.
- Yoon, H., Shin, H.J., Kim, M.J., Han, S.J., Koh, H., Kim, S., Lee, M.J. 2019. Predicting Gastroesophageal Varices Through Spleen Magnetic Resonance Elastography in Pediatric Liver Fibrosis. *World J Gastroenterol* 25(3):367-377.
- Yulianda, D., Maharani, L., Suryoputri, M.W. 2020. Penggunaan albumin oral dan albumin injeksi pada pasien sirosis hati di RSUD Prof. Dr. Margono Purwokerto. *Act Pharm Indo*. Volume 8(1):8-15.
- Zhang, G., Jazwinski, F.A. 2021. Spontaneous Bacterial Peritonitis. *JAMA* vol.325(11):1118.
- Zhou, W.C., Zhang, Q.B., Qiao, L. 2014. Pathogenesis of Liver Cirrhosis. *World Journal of Gastrology* 20(23):7312-7324.

